Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, miglustat (Zavesca®) cannot be endorsed for use within NHS Wales for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. |
||
|
||
Medicine details |
||
| Medicine name | miglustat (Zavesca®) | |
| Formulation | 100 mg capsule | |
| Reference number | 1577 | |
| Indication | For the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. |
|
| Company | Actelion Pharmaceuticals UK Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 23/07/2012 | |
| Date of issue | 27/07/2012 | |